"The wireless music box has no imaginable commercial value. Who would pay for a message sent to nobody in particular?"
David Sarnoff, American radio pioneer ; 1921
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7189541 | Botulinum toxin production method Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-p... | 03/13/2007 |
| 7160699 | Media for clostridium bacterium and processes for obtaining a clostridial toxin Animal product free (APF) media and processes for the culture and fermentation of botulinum toxin producing Clostridium botulinum bacteria. The botulinum toxin obtained can be used for formulating and compounding botulinum toxin pharmaceu... | 01/09/2007 |
| 7148041 | Animal product free media and processes for obtaining a toxin Media and processes for the fermentation of Clostridium botulinum and obtaining a botulinum toxin for use in formulating botulinum toxin pharmaceutical compositions. The growth media can contain significantly reduced levels of meat or dairy by-p... | 12/12/2006 |
| 7037680 | Recombinant light chains of neurotoxins and light chain fusion proteins for use in research and clinical therapy Botulinum neurotoxins, the most potent of all toxins, induce lethal neuromuscular paralysis by inhibiting exocytosis at the neuromuscular junction. The light chains (LC) of these dichain neurotoxins are a new class of zinc-endopeptidases that specifically cle... | 05/02/2006 |
| 6762280 | High throughput assays for the proteotytic activities of clostridial neurotoxins In this application is described substrates for high-throughput assays of clostridial neurotoxin proteolytic activities. Two types of substrates are described for use in assays for the proteolytic activities of clostridial neurotoxins: (1) modified peptides or prote... | 07/13/2004 |
| 6746677 | Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation The invention relates to certain stable vaccine compositions comprising a macrocyclic lactone compound, a milbemycin compound, an avermectin compound or mixtures thereof; at least one antigen; a dispersing agent; an adjuvant; a water soluble organic solvent; and sal... | 06/08/2004 |
| 6623775 | Treating or preventing illness growth of Clostridium difficile The present invention relates to the discovery that hop extract is useful as an antibacterial agent against the dangerous pathogens Clostridium botulinum, Clostridium difficile, and Helicobacter pylori at levels below that at which a flavor from the acids... | 09/23/2003 |
| 6558926 | Method for production of tetanus toxin using media substantially free of animal products The present invention provides a system for the growth of C. tetani and production of Tetanus Toxin for use in formulating Tetanus Toxoid preparations. The system includes growth media that contain significantly reduced levels of meat or dairy by-products... | 05/06/2003 |
| 6444209 | Hybrid botulinal neurotoxins A hybrid botulinal neurotoxin is disclosed. In one embodiment, the neurotoxin comprises a combination of a botulinal neurotoxin heavy chain and light chain, wherein the light chain and heavy chain are not of the same serotype and wherein the heavy and lig... | 09/03/2002 |
| 6428975 | Methods for determining the presence or absence of microorganisms in lipid-containing compositions The present invention provides methods of validating the sterility of compositions which contain large quantities of lipids, and especially those lipid compounds which contain quantities of bacteriocidal agents such as antibiotics. The compositions may co... | 08/06/2002 |
| 6429189 | Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases Pharmaceutical applications of a chemodenervating agent reduce pain by altering release of pain and inflammation-mediating autocoids, with a duration of action between 12-24 weeks. The limiting factor in dosing for this application is weakness and paralys... | 08/06/2002 |
| 6410305 | Treatment of animal waste A process and composition for treating an animal waste in a waste holding facility to reduce sulfides and enhance efficient degradation of large amounts of organic matter with reduced odor. The process includes administering a probiotic material capable o... | 06/25/2002 |
| 6251461 | Antimicrobial activity of hops extract against Clostridium botulinum, Clostridium difficile and Helicobacter pylori The present invention relates to the discovery that hop extract is useful as an antibacterial agent against the dangerous pathogens Clostridium botulinum, Clostridium difficile, and Helicobacter pylori at levels below that at which a flavor from the acids... | 06/26/2001 |
| 6225438 | Medium chain length PHA copolymer and process for producing same This invention relates to polymer production and in particular to a novel copolymer and a process for microbiologically producing the same. More specifically this invention provides for a poly-3-hydroxyalkanoate (PHA) that includes medium length 3-hydroxy... | 05/01/2001 |
| 6083512 | Multicomponent clostridial vaccines using saponin adjuvants Novel multicomponent clostridial vaccine formulations using readily dispersible, non-depot adjuvants, such as saponin, are disclosed. The vaccines can be administered to cattle intramusculary or subcutaneously without the severe persistent local reactions... | 07/04/2000 |
| 6063768 | Application of botulinum toxin to the management of neurogenic inflammatory disorders The present invention provides a method for the use of at least one serotype or a combination of serotypes of Botulinum neurotoxin either alone or in combination with other peptides or fusion proteins, that when administered in a safe and effective amount... | 05/16/2000 |
| 6025170 | Process for the biotechnological production of δ-decalactone and δ-dodecalactone The invention describes a process for the preparation of δ-decalactone or δ-dodecalactone by the hydrogenation of 2-decen-5-olide and 2-dodecen-5-olide, or a derivative therof, by a bacteria capable of effecting said hydrogenation, preferably by a bacte... | 02/15/2000 |
| 5965699 | Assay for the proteolytic activity of serotype a from clostridium botulinum A label-based assay is described, through modifications of substrate strure and derivatization of serum albumin, which can be used to determine type A proteolytic activity without separation of products.... | 10/12/1999 |
| 5939070 | Hybrid botulinal neurotoxins A hybrid botulinal neurotoxin is disclosed. In one embodiment, the neurotoxin comprises a combination of a botulinal neurotoxin heavy chain and light chain, wherein the light chain and heavy chain are not of the same serotype. A method for creating hybrid... | 08/17/1999 |
| 5854054 | Rathayibacter biopuresis produces cephalosporin haloperoxidase An enzyme preparation that exhibits cephalosporin haloperoxidase activity is isolatable from a microorganism species of the Rathayibacter genus. This enzyme preparation can convert cephalexin to a halogenated cephalosporin antibiotic in a single step. A p... | 12/29/1998 |
| 5852196 | 12,13,17-trihydroxy-9(z)-octadeoenoic acid and derivatives and microbial isolate for production of the acid A novel compound, 12,13,17-trihydroxy-9(Z)-octadecenoic acid (THOA) was produced from linoleic acid by microbial transformation at 25% yield. The newly isolated microbial strain catalyzing this transformation was identified as Clavibacter sp. ALA2 (Access... | 12/22/1998 |
| 5846929 | Purification of type G botulinum neurotoxin and pharmaceutical compositions thereof The isolation and purification of type G botulinum neurotoxin and complexes thereof is disclosed. Compositions containing the type G neurotoxin and the preparation of a type G toxoid are also disclosed.... | 12/08/1998 |
| 5753474 | Continuous two stage, dual path anaerobic fermentation of butanol and other organic solvents using two different strains of bacteria The instant invention describes a process for the manufacture of butanol and like volatile organic compounds by fermenting carbohydrates, mainly polysaccharide, with micro-organisms which convert carbohydrates into mainly butyric acid and other acids. The... | 05/19/1998 |
| 5648264 | Thermocellulolytic bacteria and their uses Clostridium thermocellum biovar. nov. SK522 (FERM BP-345 g) is a thermophilic cellulose decomposing bacteria, capable of solubilizing lignin and fermenting cellulose excellently. Although its temperature limit for growth is 40°-80° C., it grows best at ... | 07/15/1997 |
| 5529910 | Method for testing causative microorganisms of food poisioning and reagents therefor A method for testing causative bacterial species of food poisoning which is characterized by using two oligonucleotide primers that hybridize to opposite strands of bacterial DNA specifically, and flank a unique region in the target DNA and amplifying the... | 06/25/1996 |
| 5501968 | Thermostable cyclodextrin glycosyl transferase and processes using it Novel cyclodextrin glycosyl transferases (CGTase) can be produced by anaerobic cultivation of strains of Thermoanaerobacter or Thermoanaerobium. They are more thermostable than known CGTases and have temperature optimum about 95° C. The novel CGTases can... | 03/26/1996 |
| 5486459 | Biologically relevant methods for the rapid determination of sterility The invention is directed to biological processes and apparatus for determining the efficacy of a sterilization cycle based upon the recovery of activity of interactive enzyme systems comprising enzymes, coenzymes, catalysts, cofactors, substrates or any ... | 01/23/1996 |
| 5464818 | Protein having cell growth-stimulating and macrophage chemotactic actions, preparative method therefor and use thereof There are described a novel protein derived from Clostridium perfringens FERM BP-4584 method of obtaining the same and use thereof as an effective ingredient for treating wounds and ulcers. The protein has a molecular weight of 420,000b1;40,000 by a GPC... | 11/07/1995 |
| 5350692 | Microorganisms useful for hydrogen gas production The present invention relates to a process for preparing hydrogen gas on an industrial scale by culturing the microorganism Clostridium beijerinckii Ferm BP-3592 or the anaerobic asporogenic bacterium strain Ferm BP-3593 in a medium containing glucose and... | 09/27/1994 |
| 5350685 | Process for preparing hydrogen gas using microorganism The present invention relates to a process for preparing hydrogen gas on an industrial scale by culturing the microorganism Clostridium beijerinckii Ferm BP-3592 or the anaerobic asporogenic bacterium strain Ferm BP-3593 in a medium containing glucose and... | 09/27/1994 |
| 5334535 | Process for the preparation of optically pure diastereoisomers of tetrahydrofolate compounds using 10-formyltetrahydrofolate synthetase from clostridium A process for the preparation of optically pure diastereoisomers of tetrahydrofolate compounds is described, comprising the conversion, for example, of only the 5,6S,7,8-tetrahydrofolic acid component of a racemic mixture of 5,6,7,8-tetrahydrofolic acid t... | 08/02/1994 |
| 5332503 | Process for purifying collagenase A process for purifying crude collagenase is disclosed. The collagenase purification process includes providing a stabilized crude collagenase solution containing collagenase, pigment, toxins, bacterial materials, and proteolytic enzyme impurities includi... | 07/26/1994 |
| 5292523 | Method for growth promotion of animals and powder compositions containing killed microbial cells of bacteria belonging to genus clostridium The invention provides a method for the growth promotion of animals, comprising orally administering into animals killed microbial cells of bacteria belonging to the genus Clostridium, and also provides a powder composition, which comprises as essential i... | 03/08/1994 |
| 5266315 | Composite for Clostridium difficile diarrhea and pseudomembranous colitis A preventive and curative medical composition for Clostridium difficile diarrhea and psedomembranous colitis, which composition comprises cells or spores of a butyric acid bacterium and Vancomycin.... | 11/30/1993 |
| 5266475 | Glucose isomerases with improved affinity for D-glucose A genetically engineered glucose isomerase with improved affinity for D-glucose and the method of preparation of such a glucose isomerase are disclosed. The glucose isomerase is obtained by mutagenizing the gene of a naturally occurring glucose isomerase ... | 11/30/1993 |
| 5254465 | Process for manufacture of alkaline earth acetates A process for the manufacture of alkaline earth salts of acetic acid. Biomass is fermented under appropriate conditions to produce acetic acid, which is extracted from the fermentation broth with the aid of a basic liquid ion exchanger dissolved in an org... | 10/19/1993 |
| 5254467 | Fermentive production of 1,3-propanediol A process for the transformation of glycerol into 1,3-propanediol by microorganisms comprising fermenting the microorganisms in media having a glycerol content of from about 5% to about 20% by weight under standard anaerobic fermentation conditions and re... | 10/19/1993 |
| 5252481 | Mutant of bacterium Clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase A mutant of bacterium Clostridium histolyticum, designated Clostridum histolyticum K26 clo 88 of the following characteristics: the lack of a motility system which is a fundamental characteristic of the parenteral strain; and, the inability to biosynthesi... | 10/12/1993 |
| 5210032 | Degeneration-resistant solventogenic clostridia Butanol and acetone are major end products of a bacterial fermentation process carried out by anaerobic saccharolytic clostridia such as Clostridium acetobutylicum. However, these organisms degenerate upon repeated subculture of growing cells, thereby los... | 05/11/1993 |
| 5192673 | Mutant strain of C. acetobutylicum and process for making butanol A biologically pure asporogenic mutant of Clostridium acetobutylicum is produced by growing sporogenic C. acetobutylicum ATCC 4259 and treating the parent strain with ethane methane sulfonate. The mutant which as been designated C. acetobutylicum ATCC 550... | 03/09/1993 |